Roth MKM Initiates Coverage On ASLAN Pharma with Buy Rating, Announces Price Target of $15
Portfolio Pulse from richadhand@benzinga.com
Roth MKM analyst Dylan Dupuis initiates coverage on ASLAN Pharma (NASDAQ:ASLN) with a Buy rating and announces a price target of $15.
May 31, 2023 | 8:33 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
ASLAN Pharma receives a Buy rating from Roth MKM analyst Dylan Dupuis, with a price target of $15.
The Buy rating and $15 price target from Roth MKM analyst Dylan Dupuis indicate a positive outlook for ASLAN Pharma. This news is likely to have a positive impact on the stock price in the short term as it shows confidence in the company's potential growth and performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100